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Abstract
 
Our previous work demonstrated that cytotoxic T lymphocyte (CTL)-mediated tumor immuno-
surveillance of the 15-12RM tumor could be suppressed by a CD1d-restricted lymphocyte,
most likely a natural killer (NK) T cell, which produces interleukin (IL)-13. Here we present
evidence for the effector elements in this suppressive pathway. T cell–reconstituted recombi-
nation activating gene (RAG)2 knockout (KO) and RAG2/IL-4 receptor 
 
  
 
double KO mice
showed that inhibition of immunosurveillance requires IL-13 responsiveness by a non–T
non–B cell. Such nonlymphoid splenocytes from tumor-bearing mice produced more trans-
forming growth factor (TGF)-
 
 
 
, a potent inhibitor of CTL, ex vivo than such cells from naive
mice, and this TGF-
 
  
 
production was dependent on the presence in vivo of both IL-13 and
CD1d-restricted T cells. Ex vivo TGF-
 
  
 
production was also abrogated by depleting either
CD11b
 
  
 
or Gr-1
 
  
 
cells from the nonlymphoid cells of tumor-bearing mice. Further, blocking
TGF-
 
  
 
or depleting Gr-1
 
  
 
cells in vivo prevented the tumor recurrence, implying that TGF-
 
 
 
made by a CD11b
 
  
 
Gr-1
 
  
 
myeloid cell, in an IL-13 and CD1d-restricted T cell–dependent
mechanism, is necessary for down-regulation of tumor immunosurveillance. Identification of
this stepwise regulation of immunosurveillance, involving CD1-restricted T cells, IL-13,
myeloid cells, and TGF-
 
 
 
, explains previous observations on myeloid suppressor cells or
TGF-
 
  
 
and provides insights for targeted approaches for cancer immunotherapy, including
synergistic blockade of TGF-
 
  
 
and IL-13.
Key words: TGF-
 
  
 
• NKT cells • immunologic surveillance • myeloid cells • IL-13
 
Introduction
 
Understanding and overcoming mechanisms of tumor escape
from immunosurveillance have been a major focus of tumor
immunology. During the last decade, multiple mecha-
nisms of tumor escape from immunosurveillance have
been reported (1, 2). Immunosurveillance has been best
documented in human tumors expressing foreign viral anti-
gens, such as papillomavirus E6 and E7 in cervical cancers,
HTLV-I antigens in T cell lymphoma/leukemia, or EBV
antigens in B cell lymphoma/leukemia. Therefore, we
have used a murine tumor expressing a viral protein as a
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model for studying mechanisms of down-regulation of tu-
mor immunosurveillance (3, 4). With this mouse tumor
model, in which tumor shows a growth-regression-recur-
rence pattern, we demonstrated that regression was medi-
ated by specific CD8
 
  
 
CTLs (3). Tumor recurrence was
the result of incomplete elimination of tumor cells by
CTLs that were negatively regulated by IL-13 produced
by CD4
 
  
 
CD1d-restricted T cells, most likely NKT cells,
through the IL-4R
 
 
 
–STAT6 signaling pathway, although
this negative regulation was found to be independent of
IL-4. CD1d-restricted T cells from tumor-bearing mice
were shown to produce IL-13, and tumor recurrence was
prevented by eliminating CD1d-restricted T cells or
blocking IL-13 in vivo (4). This or a related pathway is
likely to play a role in tumor immunosurveillance for
other type of tumors, as STAT6 KO mice effectively re-
ject a breast carcinoma and a mastocytoma in two differ-
ent strains of mice (5, 6) and CD1 KO mice were resistant
to a breast carcinoma (7). We have also observed similar
inhibition of growth of a colon carcinoma and osteosar-
coma in CD1 KO mice in preliminary studies. Thus, this
pathway is possibly not limited to the gp160-expressing
tumor under study.
However, it is known that T cells generally do not ex-
press IL-13 receptors (8). Therefore, we have hypothesized
that intermediate cells may respond to IL-13 and suppress
CTL-mediated tumor immunosurveillance, and that our
earlier study had defined only the upstream half of the reg-
ulatory circuit. To test this hypothesis, we have now inves-
tigated the identity of this postulated intermediate cell and
the mechanism by which it inhibits tumor immunosurveil-
lance by CTL to define the effector elements in this sup-
pressive pathway.
Previously, TGF-
 
  
 
has been suggested to play a role in
tumor escape from immunosurveillance (9). Inhibition of
TGF-
 
  
 
by antibody or soluble receptor inhibits tumor
growth in vivo (9–13), but the mechanism has been un-
clear and not necessarily immunological. Recently Gorelik
and Flavell (14) reported that mice with T cells that do not
respond to TGF-
 
  
 
were resistant to implanted aggressive
tumor cell lines B16 and EL4. This evidence suggests that
direct action of TGF-
 
  
 
on T cells suppresses antitumor T
cell activity and results in uncontrolled outgrowth of tumor
cells. However, very little is known about what immune
mechanisms induce TGF-
 
  
 
production in tumor-bearing
animals or cancer patients, beyond production by the tu-
mor cells themselves.
Here we have put these earlier observations in context
by demonstrating that IL-13 and CD4
 
  
 
CD1d-restricted T
cells are required in vivo for TGF-
 
  
 
production by non-
lymphoid cells of myeloid origin that express both CD11b
and Gr-1. This intermediate cell and TGF-
 
  
 
were neces-
sary for down-regulation of CD8
 
  
 
CTL-mediated tumor
immunosurveillance. Connecting myeloid cells and TGF-
 
 
 
to the CD1d-restricted T cell/IL-13 regulatory pathway
puts previous separate observations on TGF-
 
  
 
or myeloid
cells by themselves into the larger context of a regulatory
 
circuit, and provides an explanation for observations on
their role in controlling tumor growth. Thus, we have now
defined the downstream half of the immunoregulatory cir-
cuit and elucidated the effector mechanism of CD1d-
restricted, T cell–mediated suppression of CTLs. Under-
standing the complete pathway suggests several potential
therapeutic target sites at which intervention could increase
antitumor immunity and inhibit tumor growth.
 
Materials and Methods
 
Mice.
 
Female BALB/c mice were purchased from Charles
River Laboratories. RAG2 KO (Taconic), RAG2/IL-4R
 
  
 
dou-
ble KO, and CD1 KO mice (4) with BALB/c background were
bred under pathogen-free conditions. Mice were maintained in a
pathogen-free facility and used at 6–10 wk of age. Animal exper-
iments were all approved by the National Cancer Institute (NCI)
Animal Care and Use Committee.
 
Reagents.
 
Purified rat anti–mouse CD4 mAb (GK1.5) was
obtained from the Frederick Cancer Research and Development
Center, NCI. A fusion protein of murine IL-13R
 
 
 
2 and human
IgG1 (sIL-13R
 
 
 
2-Fc) was made by Genetics Institute (15).
Monoclonal anti–TGF-
 
  
 
(1D11.16 specific for TGF-
 
 
 
1, TGF-
 
 
 
2, and TGF-
 
 
 
3; reference 16) and isotype-matched control an-
tibody (13C4; reference 17) were made by Genzyme. Anti-Ia,
anti-CD11b, anti-CD11c, anti-B220, anti-DX5, anti-CD4, anti-
CD8, and avidin-conjugated magnetic beads were purchased
from Miltenyi Biotec, recombinant mouse IL-2 and IL-13 were
purchased from R&D Systems, and recombinant human TGF-
 
 
 
1
was purchased from PeproTech. PE-conjugated 
 
 
 
-Galactosylcer-
amide–loaded and empty mouse CD1d tetramer were provided
by M. Kronenberg (La Jolla Institute for Allergy and Immunol-
ogy, La Jolla, CA; reference 18). PerCP-, PE-, and FITC-conju-
gated anti-CD11b (M1/70), FITC- and APC-conjugated CD11c
(HL3), FITC and biotinylated anti–Gr-1 (RB6-8C5), APC-con-
jugated anti-CD31 (MEC 13.3), and PE-conjugated anti–IL-4R
 
 
 
(mIL-4R-M1) antibodies were purchased from BD Biosciences,
and PE-conjugated anti-F4/80 antibody (A3-1) was purchased from
Caltag Laboratories. 
 
N
 
-nitro-
 
l
 
-arginine-methyl ester (
 
l
 
-NAME)
and 
 
N
 
-nitro-
 
d
 
-arginine-methyl ester (
 
d
 
-NAME) were purchased
from Sigma-Aldrich.
 
Tumor Cell Lines and Tumor Inoculation.
 
Fibrosarcoma 15-
12RM and 18Neo (3) were maintained as previously described
(3). 10
 
6 
 
15-12RM cells were injected s.c. on the right flank. To
deplete CD4
 
  
 
cells in vivo, mice were inoculated i.p. with 0.5
mg anti-CD4 mAb or control rat IgG (Sigma-Aldrich) 3 d in a
row from day 0 and twice a week thereafter. In some experi-
ments, mice were treated i.p on days 0, 1, and 3 with 0.2 mg sIL-
13R
 
 
 
2-Fc or every other day for 10 d with 0.1 mg of either
anti–TGF-
 
  
 
mAb or control mAb. For Gr-1
 
  
 
cell depletion,
mice were injected i.p. with 200, 100, 10, or 1 
 
 
 
g anti–Gr-1 an-
tibody (Cedarlane Laboratories Ltd.) on days 5, 6, 10, 15, and 20
after tumor injection. Where indicated, mice received 0.2 mg
 
l
 
-NAME or 
 
d
 
-NAME every day for 2 wk after tumor injection.
Mouse colon carcinoma line CT26 was maintained in com-
plete T cell medium (3). 20,000 CT26 cells were injected via the
tail vein into BALB/c mice. The mice were inoculated i.p. with
0.1 mg of either anti–TGF-
 
  
 
mAb or control mAb every other
day for 2 wk. At the time when control mice had developed a
sufficient number of tumor metastases (
 
 
 
3 wk after tumor inocu-
lation), all the mice were killed and evaluated for pulmonary me- 
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tastases by counting nodules in the lungs perfused with a 15% so-
lution of India ink and fixed with Feke’s solution.
 
T Cell Purification and In Vivo Transfer.
 
T cells were nega-
tively isolated from the spleen cells of wild-type or IL-4R
 
  
 
KO
BALB/c mice. Single cell suspensions of spleen cells were de-
pleted for Ia
 
 
 
, CD11b
 
 
 
, CD11c
 
 
 
, and DX5
 
  
 
cells by using mag-
netic beads (Miltenyi Biotec). 50 million purified T cells were in-
oculated into RAG2 KO or RAG2IL-4R
 
  
 
double KO mice i.v.
1 wk before 15-12RM injection.
 
CTL Generation and CTL Assay.
 
Spleen cells from 10
 
7 
 
PFU
vPE16-injected BALB/c mice were stimulated with 1 
 
 
 
M P18-
IIIB and used for CTL assay as previously described (4). In some
experiments, non–T non–NK cells were prepared from spleen
cells from both naive and 15-12RM–injected BALB/c mice by
depleting CD4
 
 
 
, CD8
 
 
 
, and DX5
 
  
 
cells by magnetic beads con-
jugated with anti-CD4, anti-CD8, and anti-DX5 antibodies
(Miltenyi Biotec). After being pulsed with 1 
 
 
 
M P18-IIIB pep-
tide, the cells were admixed with T cells from vPE16-injected
mouse spleen cells purified with magnetic beads (Miltenyi Biotec)
in complete T cell medium (3) with 20 U/ml IL-2 in the pres-
ence or absence of 50 
 
 
 
g/ml anti–TGF-
 
  
 
antibody (1D11) as in-
dicated. After 1 wk of culture, viable cells were harvested and
used as effector cells for the CTL assay as previously described (4).
 
Isolating Nonlymphoid Cells and Measurement of Ex Vivo TGF-
 
 
 
1
Production.
 
Non–T non–B non–NK cells, referred to as non-
lymphoid cells, were purified from spleen cells of BALB/c mice
by depletion of T, B, and NK cells using magnetic beads coated
with anti-CD4, anti-CD8, anti-B220, and anti-DX5 (Miltenyi
Biotec). In some experiments, CD11b
 
 
 
, CD11c
 
 
 
, or Gr-1
 
  
 
cells
were depleted using magnetic beads coated with anti-CD11b,
anti-CD11c, or streptavidin (Miltenyi Biotec) along with bio-
tinylated anti–Gr-1 antibody (BD Biosciences). 2 
 
  
 
10
 
5 
 
cells were
cultured in vitro without stimulation in a 96-well plate in 200 
 
 
 
l
X Vivo 20 medium (BioWhittaker, Inc.). At the indicated times,
100 
 
 
 
l culture medium was harvested from each well and stored
at 
 
 
 
80
 
 
 
C until TGF-
 
 
 
1 measurement. After acidification, to
convert all TGF-
 
 
 
1 to the active form, the concentration of total
TGF-
 
 
 
1 in the culture supernatant was determined by ELISA kit
(R&D Systems). All samples were assayed in triplicate. Without
acidification, no TGF-
 
 
 
1 was detected, indicating that the TGF- 
was all in the latent form. The amount of TGF- 1 production ex
vivo by 106 cells was calculated as follows: concentration of cul-
ture supernatant (pg/ml)   0.2 (ml)/(2   105/106)   pg pro-
duced per million cells.
Flow Cytometric Analysis. Spleen cells were obtained from na-
ive and 15-12RM–injected mice. The cells were stained with an-
tibodies for 30 min after blocking CD16/CD32 (2.4G2; BD Bio-
sciences) for 15 min. After washing, the cells were analyzed by
FACScan™ or FACSCaliber™ by using CELLQuest™ software
(BD Biosciences).
Morphological Study of Gr-1  CD11b  Cells. Nonlymphoid
cells prepared from BALB/c spleen cells were stained with FITC-
conjugated anti–Gr-1 and APC-conjugated anti-CD11b antibod-
ies for 30 min after blocking CD16/CD32 (BD Biosciences) for
15 min. After washing, the cells were gated on Gr-1hi CD11b 
and Gr-1int CD11b  cell populations and sorted by FACS Van-
tage™ (BD Biosciences). After washing, sorted cells were col-
lected by cytospin onto glass slides and dried completely. The
cells were stained with Wright-Giemsa stain using a Diff-Quik
stain set (Dade Behring Inc.).
Statistical Analysis. Statistical analysis was performed by a log-
rank test, one-way analysis of variance, or Student’s t test. Data
were considered significant at P   0.05.
Results
Non–T Non–B Cells Are the Cells Responding to IL-13
That Down-regulate Tumor Immunosurveillance. In BALB/c
mice injected s.c. with the fibrosarcoma 15-12RM, tumors
show a growth regression recurrence pattern. The sponta-
neous regression was mediated by CD8  CTLs (3). As we
showed previously, both IL-13 and CD4  CD1d-restricted
T cells, most likely NKT cells, the only known CD1d-
restricted T cells in the mouse (19), were necessary to down-
regulate this CTL-mediated tumor immunosurveillance (4).
To understand the mechanism of down-regulation of tumor
immunosurveillance induced by IL-13, first we examined
the direct effect of IL-13 on CTLs in vitro. Spleen cells
from mice immunized with recombinant vaccinia vPE16,
which expresses HIV gp160, were stimulated with P18 pep-
tide, the immunodominant epitope peptide of the V3 loop
of HIV gp160 responsible for much of the CTL activity
against the 15-12RM tumor (3). The cells were maintained
for 1 wk with various doses of IL-13 in addition to IL-2,
and used as effector cells in a CTL assay (Fig. 1 A). IL-13
during stimulation had no effect on CTL activity (Fig. 1 A),
nor did adding IL-13 during the CTL assay (not depicted).
These results are consistent with published reports that T
cells lack IL-13 receptors (8) and suggest that although IL-
13 is necessary for down-regulation of CTL tumor immu-
nosurveillance, it could not directly affect CTL induction or
Figure 1. TGF- 1 but not IL-13 can directly suppress CTL induction
in vitro. 4   106 spleen cells from mice immunized with vPE16 were
stimulated in vitro with 106 P18-pulsed spleen cells for 6 d. During in
vitro stimulation, in addition to IL-2 (  and  ), in A the cells were
maintained with 50 ng/ml (  and  ), 5 ng/ml (  and  ), or 0.5 ng/ml
(  and  ) of IL-13 or in B, 100 ng/ml (  and  ), 10 ng/ml (  and  ),
or 1 ng/ml (  and  ) of TGF-  was added. The cultured cells were used
for CTL assay at the E/T ratios shown. Targets were 18Neo fibroblasts
either without peptide (open symbols) or pulsed with 1  M P18-IIIB
peptide (solid symbols). The data shown are representative of three inde-
pendent experiments.Immunoregulatory Circuit Repressing Tumor Surveillance 1744
activity and that there must be other downstream steps that
directly down-regulate CTL activity.
To identify an intermediate cell that responds to IL-13
and then acts on CTLs to down-regulate immunosurveil-
lance, we performed a T cell transfer experiment using
RAG2 KO and RAG2/IL-4R  double KO recipient mice
(Fig. 2). IL-4R  is required for response to IL-13. Splenic
T cells were purified by negative selection for cells express-
ing MHC class II, CD11b, CD11c, and DX5. The latter is
expressed on NK but not NKT cells (19). The purified T
cells contained 2–3% CD1d tetramer  cells (NKT cells),
compared with 1–1.5% in spleen cells. 50 million T cells
purified from wild-type or IL-4R  KO mice were injected
i.v. into RAG2 KO and RAG2/IL-4R  double KO mice
1 wk before 15-12RM injection. RAG2 KO or RAG2/
IL-4R  double KO mice did not reject tumors at all be-
cause they lack T and B cells. However, RAG2 KO mice
receiving transferred T cells, regardless of the expression of
IL-4R  by the T cells, behaved like wild-type BALB/c
mice, implying that both CD8  effector cells and CD1d-
restricted T regulatory cells were successfully reconstituted.
Further, the fact that T cells from IL-4R  KO mice recon-
stitute as well as wild-type T cells implies that neither the
effector nor the regulatory T cells themselves need to be
able to respond to IL-13. In contrast, in RAG2/IL-4R 
double KO mice that received the same wild-type T cells,
the tumor did not recur after initial growth and regression,
even though the transferred T cells expressed IL-4R .
Thus, it is the recipient RAG2 KO cells that must express
IL-4R  to repress immunosurveillance. We have shown
previously that IL-4 was neither necessary nor sufficient for
down-regulation of tumor immunosurveillance in this sys-
tem, and that the cytokine responsible for signaling
through IL-4R   to regulate tumor immunosurveillance
was IL-13 (4). Therefore, the cells that respond to IL-13 to
mediate the down-regulation of tumor immunosurveil-
lance must derive from the RAG2 KO host, which lacks T
and B cells. We conclude that the intermediate cells re-
sponding to IL-13 and down-regulating CTL activity are
non–T non–B cells.
TGF- 1 Is Necessary for the Down-regulation of Tumor Im-
munosurveillance. To understand how non–T non–B cells
respond to IL-13 and suppress CTL induction in tumor-
bearing mice, we considered that TGF- 1 is known for its
ability to suppress lytic activity of CD8  T cell function
(20). To examine the ability of TGF- 1 to suppress CTL
function, we stimulated spleen cells of vPE16-immunized
mice in vitro for 1 wk with P18 peptide in the presence of
various doses of TGF-  and then tested these in a CTL as-
say (Fig. 1 B). When vPE16-immunized spleen cells were
stimulated in vitro in the presence of TGF- 1, cytolytic ac-
tivity was suppressed. TGF-  had no effect in the lytic assay
itself (not depicted). These results showed that in contrast to
IL-13, TGF- 1 directly down-regulates CTL induction.
If TGF- 1 is the cytokine induced by IL-13 in tumor-
bearing mice to down-regulate tumor immunosurveillance,
TGF- 1 production should be increased in non–T non–B
cells of tumor-bearing mice. To test whether TGF- 1 pro-
duction is up-regulated in tumor-bearing mice in vivo, we
purified splenic nonlymphoid cells (Thy1.2  B220  DX5 
cells) from both naive and 15-12RM–injected mice at day
3 after tumor injection, and examined TGF- 1 production
ex vivo without in vitro stimulation (Fig. 3 A). Latent
TGF- 1, although not detected at 3 h of culture (not de-
picted), was already detected in the culture supernatants of
the nonlymphoid cells from 15-12RM–injected mice after
only 6 h of culture but was undetected in cells from naive
mice at that time point (P   0.005 by Student’s t test). This
earliest time point probably reflects the in vivo activity of
these cells at the time they were removed from the mouse,
without any in vitro stimulation. By 12 h in tissue culture
plastic, even the cells from nontumor-bearing mice were
making some TGF- , suggesting a nonspecific stimulation
by the tissue culture plates or medium. Nevertheless, even
at this later time point, the cells from 15-12RM–injected
mice still produced more TGF- 1 than those from naive
mice. We also examined the kinetics of TGF- 1 produc-
tion by nonlymphoid cells (Fig. 3 B). The TGF- 1 pro-
duction by nonlymphoid cells was increased until at least
day 10 after tumor injection. Therefore, to test the hypoth-
esis that TGF- 1 was necessary for tumor recurrence in
vivo, we injected i.p. either a neutralizing anti–TGF-  or
control mAb (Fig. 3 C). Because we have previously
shown that the first 10 d after 15-12RM injection were
very critical for negative regulation of tumor immunosur-
Figure 2. Non–T non–-B cells are the cells responding to IL-13 that
down-regulate tumor immunosurveillance. RAG2 KO and RAG2/IL-4R 
KO mice were injected i.v. with 5   107 purified T cells from the spleens
of wild-type or IL-4R  KO mice. These T cells were purified by depleting
cells expressing MHC class II, CD11b, CD11c, and DX5 cells from
spleen cells by using magnetic beads conjugated with antibodies against
each molecule. 1 wk later, the mice were injected s.c. with 106 15-12RM
tumor cells. RAG2 KO or RAG2/IL-4R  KO mice lack T and B cells. T
cells from IL-4R  KO mice and nonlymphoid host cells from RAG2/IL-
4R  double KO mice cannot respond to IL-4 or IL-13. Five mice were
used for each group. The result shown is representative of three experiments.Terabe et al. 1745
veillance (4), we treated mice with mAb for the first 10 d af-
ter tumor injection. The mice treated with anti–TGF- 
were protected from recurrence of tumor similarly to anti-
CD4–treated mice. The effect of anti–TGF-  was seen only
in the recurrent phase when the difference in tumor size was
enormous ( 400 mm2 in the controls vs. none in the anti–
TGF- –treated mice). In contrast, there was little difference
in the primary tumors. Although the sizes of the primary tu-
mors during the initial growth period in anti–TGF- –
treated mice were slightly smaller than those of tumors in
control mice in all the experiments, the difference was not
significant (Fig. 3 E). These results demonstrate that TGF-
 1 is necessary for tumor recurrence. Even though increased
TGF-  production was observed through day 10 (Fig. 3 B),
starting the anti–TGF-  treatment at 5 d was too late to
make an impact on late tumor recurrence (Fig. 3 D). These
results suggest that TGF- 1 produced early after tumor in-
jection plays a critical role in down-regulation of antitumor
immunosurveillance. Therefore, we decided to measure ex
vivo TGF-  production by the nonlymphoid cells on day 3
after tumor injection. Furthermore, the fact that blockade of
TGF-  for the first 10 d is sufficient suggests that it is critical
only during the priming of CTLs, consistent with our obser-
vation that TGF-  inhibits the induction of CTLs (Fig. 2)
but not their effector function (not depicted).
For further confirmation of the role of TGF-  made by
the nonlymphoid cells from 15-12RM–injected mice in
down-regulation of CTLs, we examined the effect of
splenic non–T non–NK cells from 15-12RM–injected
mice on CTL induction in vitro. Purified splenic T cells
from mice immunized with recombinant HIV gp160-
expressing vaccinia vPE16 were stimulated with P18 pep-
tide-pulsed non–T non–NK spleen cells (depleted of CD4 ,
CD8 , and DX5  cells by magnetic beads) from naive or
15-12RM–injected mice at day 3 after injection. The cells
were maintained with IL-2 and with or without 50  g/ml
anti–TGF-  antibody (1D11) for 1 wk, and used as effector
cells in a CTL assay (Fig. 4). The CTL cultured with non–T
non–NK cells from 15-12RM–injected mice showed
lower cytolytic activity than those cultured with the cells
from naive mice. However, this suppression was fully over-
come by adding anti–TGF-  antibody during the culture.
This result indicates that TGF-  made ex vivo by nonlym-
phoid cells (Fig. 3, A and B) has the potential to directly
suppress CTL induction.
Figure 3. TGF- 1 production was increased in nonlymphoid spleen
cells (non–T non–B non–NK cells) from 15-12RM–injected BALB/c
mice and anti–TGF-  antibody prevents tumor recurrence. (A) On day 3
after 15-12RM injection, freshly isolated nonlymphoid cells from naive
BALB/c (open bar) and 15-12RM tumor-injected BALB/c mice (solid
bar) were examined for TGF- 1 production ex vivo. Nonlymphoid cells
were purified from spleen cells of BALB/c mice by depletion of T cells, B
cells, and NK cells. 2   105 cells were cultured in vitro without stimulation in
a 96-well plate in 200  l X Vivo 20 medium. The concentration of
TGF- 1 was determined by ELISA. Each value shows the average   SD
of triplicate assay. P   0.005 at 6 h and P   0.01 at 12 h with Student’s t
test between naive and tumor-bearing groups. Error bars not shown are
too small to be seen on this scale. This experiment is representative of 10
experiments with similar results. (B) Freshly isolated nonlymphoid cells
were prepared from 15-12RM–injected mice at different time points after
tumor injection, and were examined for TGF- 1 production ex vivo as
described in A. (C) Anti-CD4–treated mice ( ), anti–TGF- –treated
mice ( ), or control isotype-matched antibody-treated ( ) BALB/c
mice (five per group) were injected with 106 15-12RM cells s.c. 0.5 mg
of the anti-CD4 mAb was inoculated on days 0, 1, 2, 6, and 10 after tumor
injection. 100  g anti–TGF-  mAb or isotype-matched control mAb
were injected every other day from days 0 to 10. P   0.05 with log-rank
test between the control group and the anti–TGF-  group. This experiment
is representative of three experiments with similar results. (D) After s.c.
inoculation of 15-12RM cells, the mice (five per group) were treated
with 100  g anti–TGF-  antibody from day 0 ( ) or day 5 ( ), or control
isotype-matched antibody ( ) every other day for 10 d. (E) Size of primary
tumors in 15-12RM–injected BALB/c mice treated with 100  g anti–
TGF-  mAb ( ) i.p. every other day for 10 d or without any antibody
treatment ( ). The mice were inoculated s.c. with 106 15-12RM cells.
Tumor size was measured in two perpendicular dimensions with calipers
every other day. The vertical axis shows tumor area measured as the
product of these two dimensions. This experiment is representative of
four independent experiments. (F) BALB/c mice (five per group) injected
with 2   105 CT26 were treated with 0.1 mg anti–TGF-  mAb or isotype-
matched control mAb every other day for 2 wk. On day 21, the mice
were killed and the lungs were perfused with a 15% solution of India ink.
After fixation by Fekete’s solution, the number of nodules was macro-
scopically counted. The maximum number of the nodules counted per
lung was 250. The mean number of nodules is indicated as horizontal
bars. P   0.0001 with one way analysis of variance test for the anti–TGF- 
group compared with control and control mAb groups. Similar results
were obtained in another experiment.Immunoregulatory Circuit Repressing Tumor Surveillance 1746
Recently we found that the negative immunoregulatory
pathway involving CD1d-restricted T cells and IL-13,
which we originally studied using the 15-12RM mouse tu-
mor, is also active in the mouse lung metastasis model of
syngeneic colon carcinoma CT26, to be reported else-
where (unpublished data). Therefore, we also tested the ef-
fect of anti–TGF-  on tumor growth in vivo by using this
tumor system (Fig. 3 F). Anti–TGF-  treatment signifi-
cantly reduced the number of lung metasases. This result
indicates that the role of TGF-  in down-regulation of
CTL-mediated tumor immunosurveillance is not unique to
the 15-12RM fibrosarcoma.
TGF- 1 Production Is Induced by IL-13 or CD1-restricted T
Cells in Tumor-bearing Mice. Although the results sug-
gested that TGF- 1 might be induced by IL-13 and act
downstream to down-regulate CTL-mediated tumor im-
munosurveillance, they did not rule out the possibility that
both IL-13 and TGF- 1 were necessary and acting in par-
allel to inhibit tumor immunosurveillance, albeit on differ-
ent cell populations. To distinguish between these possibil-
ities, we tested the effect of in vivo IL-13 inhibitor
treatment, which protects mice from tumor recurrence, on
ex vivo TGF- 1 production of splenic nonlymphoid cells
from tumor-bearing mice 3 d after tumor inoculation (Fig.
5 A). The IL-13 inhibitor treatment reduced the TGF- 1
level almost to that seen in naive mice. As we have previ-
ously shown that CD1d-restricted T cells were responsible
for IL-13 production induced in tumor-bearing mice and
CD1 KO mice that lack these cells resisted tumor recur-
rence (4), we also examined the TGF- 1 production in the
splenic nonlymphoid cells from CD1 KO mice 3 d after
tumor injection. The nonlymphoid cells from CD1 KO
mice failed to produce TGF- 1 immediately ex vivo, in
contrast to the cells from wild-type BALB/c mice (Fig. 5
B). Thus, TGF- 1 expression by nonlymphoid cells of tu-
mor-bearing animals is dependent in vivo on IL-13 and
CD1d-restricted T cells.
CD11b  Gr-1  Cells Were the Major Source of TGF- 1 in
Tumor-bearing Mice and Necessary for Tumor Recurrence.
The splenic nonlymphoid cells include CD11b  (45.33  
10.23% in naive mice, 33.72   8.61% in tumor-bearing
mice), CD11c  (3.78     1.21% in naive mice, 3.47  
1.76% in tumor-bearing mice), F4/80  (23.75   9.80% in
naive mice, 17.83   7.21% in tumor-bearing mice), and
Gr-1  cells (45.09   7.59% in naive mice, 35.92   11.88%
in tumor-bearing mice). Among the CD11b  cells, almost
80% (37.52   7.72% and 28.16   10.68% of nonlymphoid
spleen cells in naive and tumor-bearing mice) were positive
for Gr-1 and  50% (23.75   9.8% and 17.83   7.21%)
were positive for F4/80, but  10% were CD11c . Most of
the CD11c  cells were myeloid dendritic cells that also ex-
pressed CD11b (Fig. 6).
To determine which among the splenic nonlymphoid
cells make TGF- 1, we depleted CD11b , CD11c , or
Gr-1  cells from splenic nonlymphoid cells and measured
TGF- 1 levels in the supernatants of the ex vivo cultures
(Fig. 7, A and B). Surprisingly, depletion of either CD11b 
or Gr-1  cells almost completely abrogated TGF- 1 pro-
duction by nonlymphoid cells from tumor-bearing mice.
However, removing CD11c  cells did not have an effect
on the TGF- 1 level at 12 h, although it did at 6 h,
whereas the effect of either CD11b or Gr-1 depletion per-
sisted at 12 h, indicating that CD11c  cells were less critical
than CD11b  Gr-1  double positive cells for TGF-  pro-
duction (Fig. 7 A). These results suggested that although
CD11c  cells may play some role, among the cells express-
Figure 4. CTL induction was down-regulated by non–T non–NK cells
from 15-12RM–injected mice through TGF- . On day 3 after 15-12RM
injection, non–T non–NK cells were prepared from spleen cells of tumor-
bearing (  and  , and   and  ) and naive BALB/c mice (  and  , and
  and  ) by negatively depleting CD4 , CD8 , and DX5  cells, and
pulsed with 1  M P18 peptide. Splenic T cells from vPE16-immunized
mice were stimulated in vitro in the presence of these non–T non–NK
cells for 1 wk. In addition to IL-2 added to all cultures, 50  g/ml anti–
TGF-  was added (solid symbols) or omitted (open symbols) during in
vitro stimulation. The cultured cells were harvested and used for CTL assay.
Targets were 18Neo fibroblasts pulsed either with P18 peptide (  and  ,
and   and  ) or without peptide (  and  , and   and  ). A similar result
was obtained in another independent experiment.
Figure 5. In vivo TGF- 1 production was down-regulated in IL-13
inhibitor treated wild-type mice or CD1 KO mice injected with 15-12RM
tumor cells. (A) On day 3 after 15-12RM tumor injection, freshly isolated
nonlymphoid cells from naive (open bar), 15-12RM tumor-injected mice
(solid bar), and 15-12RM tumor-injected mice treated with IL-13 inhibitor
(gray bar) were examined for TGF- 1 production ex vivo. 0.2 mg IL-13
inhibitor (sIL-13R 2-Fc) was administrated i.p. on days 0, 1, and 2 after
tumor injection. (B) Naive wild-type BALB/c (open bar), 15-12RM tumor-
injected wild-type BALB/c (solid bar), and tumor-injected CD1 KO
BALB/c mice (gray bar) were used as a source of nonlymphoid cells on
day 3 of tumor injection. As in Fig. 3 A, in both A and B, 2   105 cells
purified were cultured in vitro without stimulation. The culture supernatant
was collected at 6 h and the concentration of TGF- 1 was determined by
ELISA. Each value shows the average   SD of triplicate assay. Error bars
not shown are too small to be seen on this scale. Similar results were
obtained in three independent experiments.Terabe et al. 1747
ing CD11b, CD11b  Gr-1  double positive cells were the
major source of TGF- 1 production by nonlymphoid cells
from 15-12RM–injected mice. We detected these cells pri-
marily in the spleen, not draining lymph nodes, where their
numbers were inadequate for study.
Therefore, we examined the role of Gr-1  cells in down-
regulation of tumor immunosurveillance in vivo. Mice
were treated with various doses (200, 100, 10, and 1  g) of
anti–Gr-1. Among the doses, the group of mice treated
with 1  g antibody from days 5–20 after tumor injection
were protected from tumor recurrence (Fig. 7 C). (At high
doses of anti–Gr-1 mAbs, tumor never even regressed, pre-
sumably due to immunodeficiency from depletion of anti-
gen-presenting cells, so the recurrence could not be studied
[not depicted]). Thus, Gr-1  cells were not only necessary
for ex vivo TGF- 1 production, but also in fact necessary
for down-regulation of immunosurveillance in vivo.
The results indicated that the intermediate cell in the
downstream effector arm of the circuit is the Gr-1 
CD11b  cell. To better characterize these cells, we exam-
ined the expression of CD11c, CD31, and IL-4R  on Gr-1 
CD11b  cells (Fig. 8 A) and their morphology (Fig. 8 B).
F4/80 was expressed on  75% of the Gr-1  CD11b  cells
from both naive and 15-12RM–injected mice. CD31 was
expressed relatively higher on the cells from tumor-bearing
mouse compared with the cells from naive mice (averages
among several experiments were 24 and 19% in tumor-
Figure 6. Flow cytometric staining of splenic nonlymphoid cells from
naive and 15-12RM tumor-injected BALB/c mice. Nonlymphoid cells
were prepared from spleen cells of naive and 15-12RM–injected mice
(day 3) by depleting CD4 , CD8 , B220 , and DX5  cells with magnetic
beads. The cells were stained with PE- and FITC-conjugated anti-
CD11b, PE-conjugated anti-CD11c, FITC-conjugated anti-F4/80, and
FITC-conjugated anti–Gr-1, washed, and analyzed by flow cytometry.
This experiment is representative of 10 experiments with similar results.
Figure 7. CD11b  cells and Gr-1  cells are the major source of TGF- 1
and necessary for down-regulation of tumor immunosurveillance. (A and
B) On day 3 after 15-12RM injection, nonlymphoid spleen cells were
purified from naive (open bar) and tumor-injected BALB/c mice (solid
bars) as in Fig. 3 A. CD11b  (hatched bars) or CD11c  (tightly dotted)
were depleted with magnetic beads during purification of the cells from
tumor-injected mice in A. CD11b  (hatched bars) or Gr-1  (dotted bars)
cells were depleted during purification of the cells from tumor-injected
mice, the latter using biotinylated antibody and avidin-coated magnetic
beads in B. As in Fig. 3 A, in both A and B, 2   105 cells were cultured in
vitro without stimulation. The concentration of TGF- 1 in media was
determined by ELISA. Each value shows the average   SD of triplicate
assay. CD11b - and Gr-1 –depleted cells produced significantly less
TGF- 1 (P   0.001, respectively) than the untreated cells from tumor-
bearing mice. Error bars not shown are too small to be seen on this scale.
This experiment is representative of three experiments with similar results.
(C) Anti–Gr-1–treated mice ( ) or control BALB/c mice ( ; five per
group) were injected with 106 15-12RM cells s.c. The anti–Gr-1 antibody
(1  g) was inoculated on days 5, 6, 10, 15, and 20 after 15-12RM injection.
P   0.05 with log-rank test between the control group and the anti–Gr-1–
treated group. This experiment is representative of three experiments
with similar results.Immunoregulatory Circuit Repressing Tumor Surveillance 1748
bearing and naive mice, respectively), although the differ-
ence was not significant. IL-4R , a component of the IL-
13 receptor, was also expressed on the Gr-1  CD11b  cells
almost at the same level on naive and tumor-bearing mice–
derived cells (15–20%). Expression of IL-4R  on the Gr-1 
CD11b  cells suggested that the Gr-1  CD11b  cells ex-
press IL-13 receptor. This result is consistent with the result
in Fig. 5 A that in vivo blockade of IL-13 reduced ex vivo
TGF-  production by these cells.
We also looked at the morphology of Gr-1  CD11b 
cells after purifying the cells by preparative sorting and
staining by the Wright-Giemsa method (Fig. 8 B). Because
there were two distinct cell populations among the Gr-1 
CD11b  cells based on the fluorescent intensity of Gr-1
staining, which we referred to as Gr-1hi CD11b  and Gr-
1int CD11b , we sorted each cell population and examined
its morphology. Gr-1hi CD11b  cells from both naive and
15-12RM–injected mice were primarily mature and some
immature neutrophils, and no difference was observed be-
tween the cells from naive and 15-12RM–injected mice
(Fig. 8 B, top). Gr-1int CD11b  cells (Fig. 8 B, bottom)
represented primarily immature myeloid cells, so-called
“bands” (Fig. 8 B, arrowheads), with some immature
monocytes (Fig. 8 B, arrows). The population from the 15-
12RM–injected mice contained relatively fewer mono-
cytes than the cells from the naive mice.
Because some studies reported that Gr-1  CD11b  my-
eloid cells induced by tumors suppress T cell responses with
nitric oxide (NO), we tested a possible role of NO in vivo
by treating mice with l-NAME (21), which is reported to
inhibit inducible NO synthase in vivo. The mice were
treated with 0.2 mg of either l-NAME or d-NAME as a
control every day for 2 wk after tumor inoculation. l-NAME
treatment did not alter tumor growth in vivo (Fig. 9).
Therefore, in 15-12RM–injected mice, NO is not neces-
sary for negative regulation of CD8  CTLs.
Taken together, our results show that in tumor-bearing
mice, IL-13 and CD1d-restricted T cells upstream are nec-
essary for TGF- 1 production by CD11b  Gr-1  cells
downstream, which negatively regulates CTL-mediated
immunosurveillance of tumors.
Discussion
We have previously shown that IL-13 made by CD4 
CD1d-restricted T cells, most likely NKT cells, is necessary
Figure 8. Characterization of Gr-1  CD11b  cells.
On day 3 after 15-12RM injection, single cell suspen-
sions of spleen cells from tumor-bearing and naive
BALB/c mice were prepared. (A) The cells were
stained with FITC-conjugated anti–Gr-1, Per-CP–
conjugated anti-CD11b antibodies in combination
with PE-conjugated anti-F4/80, APC-conjugated
anti-CD31, or PE-conjugated anti–IL-4R  antibodies
and analyzed by flow cytometry. During the analysis
of the data acquired, we first gated on Gr-1  CD11b 
cells and analyzed for the expression of other molecules.
The numbers indicated are the percentage of the cells
positive for each marker among the Gr-1  CD11b 
cells. (B) Nonlymphoid cells were stained with
FITC-conjugated anti–Gr-1, Per-CP–conjugated
anti-CD11b antibodies. The cells were preparatively
sorted by flow cytometry to select Gr-1hi CD11b 
(top) and Gr-1int CD11b  populations (bottom). The
sorted cells were collected by cytospin on glass slides,
dried overnight, and stained with Wright-Giemsa
stain. Pictures were taken under a microscope at  20.
Arrows indicate monocytes and arrowheads indicate
immature granulocytes with band morphology.
Figure 9. In vivo blockade of NO production did not alter tumor
growth. BALB/c mice (five per group) were injected with 106 15-12RM
cells s.c. Where indicated, mice were treated with 0.2 mg l-NAME ( )
or d-NAME ( ) every day for 2 wk. Control mice were inoculated with
tumors without other treatment ( ). Similar results were obtained in an
independent experiment.Terabe et al. 1749
for down-regulation of CD8  CTL-mediated tumor im-
munosurveillance through a IL-4R –STAT6 signal path-
way (4). We also recently reported that removing this neg-
ative regulatory pathway improves efficacy of antiviral
vaccines (22). However, because IL-13 could not directly
act on T cells, we attempted to find the missing link to de-
fine the downstream effector half of this novel immunoreg-
ulatory pathway. Here we have shown that TGF-  pro-
duced by CD11b   Gr-1   cells induced by IL-13 and
CD1d-restricted T cells is necessary for down-regulation of
CTL-mediated tumor immunosurveillance, completing
this regulatory circuit (Fig. 10).
Blocking TGF-  by neutralizing antibody in vivo pro-
tected mice from tumor recurrence, but not from primary
tumor growth. Because the primary tumor growth is nec-
essary to elicit a CTL response, the absence of CTLs at
early time points may explain the inability to suppress pri-
mary tumor growth.
Recent reports showed that blocking TGF-  by anti-
body or soluble receptor inhibited tumor growth, but the
mechanism was unclear and not shown to be CTL medi-
ated (9–13). In addition, the mechanisms of immunologic
induction of TGF-  production and the source of this cy-
tokine in tumor models have not been well studied, ex-
cept for the fact that tumor cells are known to make this
cytokine. This study defines the immunologic source and
puts TGF-  in the context of a broader regulatory circuit.
In our tumor model, although 15-12RM cells can make
TGF-  (unpublished data), TGF-  produced by tumor
cells cannot play a critical role in the negative regulation
of tumor immunosurveillance because mice deficient for
CD4  T cells or CD1d-restricted T cells were resistant to
tumor recurrence (3, 4), even though in both cases tumor
cells could still make TGF- . Therefore, we hypothesized
that a host cell induced by IL-13 might be responsible for
relevant TGF-  production, as we have now confirmed.
Analogously, in mice expressing the Tsk mutation (TSK/ 
mice), which results in a scleroderma-like syndrome
characterized by cutaneous hyperplasia, emphysema, car-
diac hypertrophy, and autoantibodies specific for topo-
isomerase I, RNA polymerase I, and fibrillin-1, IL-4 act-
ing through STAT6 induces TGF-   production by
fibroblasts (23). It is likely that CTL priming occurs in the
draining lymph nodes and/or spleen, where we have ob-
served TGF-   production by myeloid cells, and that
TGF-  production by the tumor itself is insufficient to af-
fect this distant response.
CD11b  Gr-1  cells, which are myeloid cells or granu-
locytes (24), were the major source of TGF-  in tumor-
bearing mice. Some CD11b  Gr-1  cells are also known
as natural suppressor cells (25). Similar cells have been
found under many different conditions: recombinant vi-
rus–immunized mice (26, 27), tumor-bearing mice (28–
30), superantigen-induced T cell tolerance (31–33), che-
motherapy with cyclophosphamide (34, 35), parasite
infection (36–39), and vitamin A deficiency (40). Some
myeloid cells have also been described to inhibit T cells in
human cancer patients (41, 42). Consistent with our ob-
servation that some Gr-1  CD11b  cells express the IL-
4R  chain, also necessary for signal transduction of IL-13,
it has been reported that this cell is also induced in vitro
by IL-4 (27). However, an immunologic mechanism by
which myeloid cells are activated in tumor-bearing mice
was unknown. Here we show the novel CD1d-restricted
T cell/IL-13 regulatory circuit activates these cells to pro-
duce TGF- . Although these myeloid cells have been de-
scribed in other contexts above, and the relationship be-
tween IL-13 and TGF-   production has been seen in
nontumor systems (see below), we believe that the tumor
plays a role in initiating this pathway. We have previously
shown that CD1d-restricted T cells from tumor-bearing
mice express more IL-13 than CD1d-restricted T cells
from control mice (4), and this study (Figs. 3 and 5) shows
that TGF-  production by nonlymphoid cells is increased
in tumor-bearing mice. Although the mechanism by
which tumor growth induces these cytokines is unknown,
we speculate that a tumor glycolipid is presented by CD1d
on dendritic cells to activate CD1d-restricted T cells to
make IL-13 to initiate the process. Indeed there have been
several reports demonstrating that glycolipids from tumors
were presented by CD1d molecules and able to stimulate
NKT cells (43, 44). We believe the most likely interpreta-
tion of all the results together is that in tumor-inoculated
mice, first, inoculated tumor cells induce IL-13 produc-
tion by CD4  CD1d-restricted T cells (4), and second,
this IL-13 is necessary for CD11b  Gr-1  cells expressing
IL-13 receptor to produce TGF-  that inhibits CTL in-
duction. IL-13 may induce TGF-  production by my-
eloid cells but not increase their numbers, as suggested by
the lack of increase in CD11b  or Gr-1  cells in the
Figure 10. Proposed model of negative immunoregulatory circuit of
CTL-mediated tumor immunosurveillance mediated by TGF- , myeloid
cells, IL-13, and CD1d-restricted T cells, probably NKT cells. Tumor
antigen (glycolipid) presented by antigen-presenting cells via the CD1d
molecule is recognized by and activates CD1d-restricted CD4  NKT
cells. The activated CD4  NKT cell produces IL-13, which acts on Gr-1 
CD11b  myeloid cells that express the IL-13 receptor. The Gr-1 
CD11b  myeloid cell produces TGF-  to suppress CD8  CTLs (CTL)
that can kill tumor cells, thereby down-regulating tumor immunosur-
veillance. This pathway is able to be blocked by IL-13 inhibitor and anti–
TGF-  antibody.Immunoregulatory Circuit Repressing Tumor Surveillance 1750
spleens of tumor-bearing mice. It appears that IL-13 is
necessary but not sufficient, as we have been unable to
mimic the in vivo results by simply adding IL-13 to spleen
cell cultures (unpublished data).
The mechanism of immunosuppression by CD11b  Gr-1 
cells has been unclear, with different candidate molecules
made by this cell population reported including TGF- 
(27, 33), NO (29, 30, 34, 35, 38), prostaglandin (38), and
peroxide (29, 41). Most of these mediators were studied in
vitro. Thus, although the potential roles of the other im-
munosuppressive mediators are difficult to study in vivo, it
is clear that in our tumor model, at least TGF-  is neces-
sary but NO is not necessary for down-regulation of tumor
immunosurveillance in vivo. Further, whereas TGF-  (14)
and Gr-1  myeloid cells (25) have each been found sepa-
rately to play a role in inhibiting tumor immunosurveil-
lance, as cited above, neither the immune source for the
TGF-  nor the mechanism for activation of the myeloid
suppressor cells was known. Here we show that Gr-1  my-
eloid cells activated by IL-13 are the main immunologic
source of differential TGF-  production in tumor-bearing
and nontumor-bearing mice, but more importantly, that
the two together represent the downstream effector half of
a larger immunoregulatory pathway, putting each compo-
nent in a larger context (Fig. 10).
Two findings in unrelated systems support our conclu-
sions and indicate that this pathway is not confined to tu-
mor immunity. In lung fibrosis (45), organ-specific overex-
pression of IL-13 transgene selectively up-regulated TGF- 
production by macrophages that caused fibrosis in the lung.
In helminth infection, treating mice with the IL-13 inhibi-
tor blocked the development of hepatic and lung fibrosis
(46) and there is some evidence suggesting TGF-  involve-
ment (47). Thus, an IL-13–TGF-  axis may play a critical
role not only in immune responses but also in other physi-
ological processes.
In conclusion, we have now closed the loop in defining
a novel immunoregulatory circuit, identifying the down-
stream effector mechanism in the proposed pathway (Fig.
10). Tumor growth induces CD1d-restricted CD4  NKT
cells to produce IL-13, which is necessary for CD11b  Gr-1 
cells to produce TGF- , and this TGF-  directly represses
antitumor activity of CTLs. Neutralizing TGF-  or deplet-
ing immature myeloid cells may provide a unique opportu-
nity for designing optimal immunotherapy for cancer.
Alternatively, neutralizing both TGF-   and IL-13 may
achieve synergy. Thus, identification here of this stepwise
regulation of tumor immunosurveillance may provide in-
sights for new approaches for cancer immunotherapy.
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